An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Mar 2022 – Mar 2024Where it's discussed
-
X / Twitter10 posts
-
News3 articles
-
Blogs3 articles
-
YouTube2 videos
-
Facebook2 posts
AI synopsis
What people are saying
The overall discussions demonstrate a moderate level of engagement, with mentions of specific conditions like apical subpleural fibrosis and traction bronchiectasis, illustrating interest in how the classification influences diagnostic and prognostic understanding; the tone is mostly informational, reflecting curiosity rather than strong agreement or disagreement.
The discussions do not show clear support or opposition to the publication, indicating neutrality.
The posts reflect some curiosity and concern about specific lung conditions related to the classification update.
Participants are engaging with content through details about diseases and diagnostic methods, showing moderate involvement.
The discussions suggest recognition of the importance of the classification, but limited evidence of widespread impact or advocacy.
Abstract in brief
- The 2023 update to the American Thoracic Society-European Respiratory Society classification of idiopathic interstitial pneumonias (IIPs) reflects significant progress since 2002, including better definitions of certain conditions like nonspecific interstitial pneumonia and more common use of less invasive diagnostic methods.
- The new classification emphasizes understanding the clinical behavior of IIPs, introduces categories for difficult-to-classify cases, and highlights rare lung diseases and the potential role of molecular markers in diagnosis, prognosis, and treatment.
- Overall, this update summarizes important advances over the past decade, aiming to improve diagnosis, classification, and management of these complex lung diseases through multidisciplinary and evolving approaches.
Top posts
Most liked on X and Bluesky#PPFE: ➡️ Apical subpleural fibrosis, traction bronchiectasis, & parenchymal distortion ➡️ Association w/ or w/o other #ILDs ➡️ Mean age 57 w/o sex predilection ➡️ Disease progression in 60%, death in 40% (3-5 years from sx onset) https://t.co/l7McdEXanz
Referències: doi:10.1164/rccm.201308-1483ST https://t.co/sA6afL4kYn
RT @ESTI_Society:
RT @ESTI_Society:
RT @ESTI_Society:
All mentions
Updated Classification of Idiopathic Interstitial Pneumonias 2023
Updated Classification of Idiopathic Interstitial Pneumonias in 2023
The 2023 update to the ATS-ERS classification reflects significant progress including better definitions, less invasive diagnostics, and understanding of clinical behavior. It emphasizes the role of molecular markers…
備忘録 間質性肺炎 終末期 モルヒネ内服 群馬大で臨床試験 https://t.co/BnwfomzGwK
Referències: doi:10.1164/rccm.201308-1483ST https://t.co/sA6afL4kYn
RT @ESTI_Society:
RT @ESTI_Society:
RT @ESTI_Society:
RT @ESTI_Society:
RT @ESTI_Society:
RT @ESTI_Society:
#PPFE: ➡️ Apical subpleural fibrosis, traction bronchiectasis, & parenchymal distortion ➡️ Association w/ or w/o other #ILDs ➡️ Mean age 57 w/o sex predilection ➡️ Disease progression in 60%, death in 40% (3-5 years from sx onset) https://t.co/l7McdEXanz
E
M
RH
AB
JC
LC
O焼
JM
ET
P